The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Abstract
Background and Objective.: There seems to be a strong causal relationship between allergy and the origins of asthma. Susceptibility to both is determined by a combination of genetics and environment acting through a complex network of cytokines. Nearly 90% of affected children have positive skin tests indicating the presence of specific immunoglobulin E (IgE), with sensitivity to house dust mite, Alternaria, cockroach, cat, and dog most closely linked to the disease. Greater exposure to house dust mite during infancy leads to earlier onset of wheezing, and elevated serum IgE levels correlate with the appearance of asthma symptoms. Specific IgE binds to high-affinity (FcεRI) receptors on mast cells and basophils. The IgE-mediated reactions that follow exposure of sensitized mast cells to an allergen are designated early- and late-phase asthmatic responses (EAR and LAR). EAR is characterized by release of histamine and other preformed mediators within 1 hour of allergen exposure. It is often followed by LAR, an infiltration of the airways by inflammatory cells associated with an episode of more prolonged, and usually more severe airflow obstruction, 4 to 8 hours after antigen exposure. Chronic airway symptoms result from persistent LAR caused by continuous allergen exposure. IgE antibodies are capable of passive transfer of both EAR and LAR sensitivity. IgE-mediated mast cell activation contributes to chronic tissue eosinophilia and airway remodeling, with permanent loss in pulmonary function. Omalizumab (rhuMAb-E25) is a recombinant, humanized, monoclonal anti-IgE antibody of mouse origin developed for the treatment of IgE-mediated diseases. Omalizumab binds to free IgE at the same site as the high-affinity receptor. Although it attaches to free IgE, it does not bind to IgA, IgG, or cell-bound IgE. It therefore does not induce cross-linking of cell-bound IgE, which would lead to the release of allergic mediators. It has been reported to decrease serum IgE levels in a dose-dependent manner, inhibit EAR and LAR, and cause a down-regulation of FcεRI receptors on basophils. Omalizumab has been reported to be safe and effective in improving asthma control and reducing the requirement for oral and inhaled corticosteroids. This double-blind, randomized, placebo-controlled study evaluated the safety, steroid-sparing effects, and impact on disease exacerbations of omalizumab in the treatment of childhood asthma. Methods.: Participants were 334 males and premenarchal females aged 6 to 12 years, with moderate to severe allergic asthma requiring treatment with inhaled corticosteroids. During a run-in phase, all children were switched to equivalent doses of beclomethasone dipropionate (BDP), and the dose was adjusted to assure maintenance of asthma control achieved with previous corticosteroid treatment. Children were randomized to subcutaneously administered placebo (N = 109) or omalizumab (N = 225) at a dose based on body weight and initial serum IgE (0.016 mg/kg/IgE [IU/mL] per 4 weeks). BDP dose (initial range 168–420 μg/d) was kept stable for 16 weeks (stable-steroid phase), reduced over 8 weeks to the minimum effective dose (steroid-reduction phase), and maintained constant for the final 4 weeks. Results.: More participants in the omalizumab group decreased their BDP dose, and their reduction was greater than that of the placebo group (median reduction 100% vs 66.7%). BDP was withdrawn completely in 55% of the omalizumab group versus 39% of the placebo group. The incidence and the frequency of asthma exacerbations requiring treatment with doubling of BDP dose or systemic corticosteroids were lower in the omalizumab group. The treatment differences were statistically significant during the steroid-reduction phase, during which fewer participants in the omalizumab group had asthma exacerbation episodes (18.2% vs 38.5%), and the mean number of episodes per patient was smaller than with placebo (0.42 vs 2.72). Five asthma exacerbations requiring hospitalization all occurred in the placebo group. Participants' and investigators' global evaluations of treatment effectiveness were more favorable for omalizumab than placebo. Investigators rated effectiveness excellent for 31.5% of the omalizumab group versus 16.3% of the placebo group and good for 44.7% of the omalizumab group versus 32.7% of the placebo group. There was little change in asthma symptom scores or spirometry measurements during either the stable-steroid or steroid dose-reduction phase, with minimal differences between the treatment groups. The requirement for rescue medication in the omalizumab group during both the stable-steroid and steroid dose-reduction phases was consistently lower than at baseline. At week 28, the median number of puffs of rescue medication taken daily was 0 in the omalizumab group and 0.46 in the placebo group. The change from baseline was significant in favor of omalizumab. Over the entire treatment period, patients in the omalizumab group missed a mean of 0.65 school days, compared with a mean of 1.21 days in the placebo group. The mean number of unscheduled medical contacts attributable to asthma-related medical problems was significantly smaller in the omalizumab group than in the placebo group throughout the treatment period (0.15 vs 5.35). Median reduction in serum free IgE was 95% to 99% among omalizumab patients. Median free IgE ranged from 133 to 790 IU/mL at baseline and was in the range of 6 to 9 IU/mL during the treatment period. The dosing scheme used in the trial therefore effectively reduced serum IgE in patients with initial concentrations as high as 1300 IU/mL. There was no reduction in free IgE in the placebo group. Omalizumab treatment was well tolerated. There were no serious treatment-related adverse events. The frequency and types of all adverse events were similar in the omalizumab and placebo groups. The majority of adverse events were mild to moderate in severity. No adverse events suggestive of serum sickness or immune complex formation were observed. Study-drug–related adverse events occurred more frequently in the omalizumab group than in the placebo group (6.2% vs 0.9%). Urticaria was reported in 9 omalizumab patients (4%) compared with 1 (0.9%) placebo patient and was mild or moderate in nearly all cases. Conclusion.: Treatment with omalizumab is safe in children with asthma. It reduces the requirement for inhaled corticosteroids while protecting against disease exacerbation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,988
Asthma and Wheezing in the First Six Years of Life
Martinez, F. D., Wright, A. L., Taussig, L. M., Holberg, C. J., Halonen, M., & Morgan, W. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501193320301 · Cited by 3,823
Guidelines for the diagnosis and management of asthma.
Solomon, P. A. (1992) · PubMed · Cited by 2,004
Allergy: Principles and Practice.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-817_10 · Cited by 1,696
Sporik, R., Holgate, S. T., Platts-Mills, T. A. E., & Cogswell, J. J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008233230802 · Cited by 1,648
National Asthma Education and Prevention Program
VanGraafeiland, B. (2002) · The Nurse Practitioner · doi:10.1097/00006205-200206001-00003 · Cited by 1,091
IMMUNOLOGIC BASIS OF ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESS
Wills-Karp, M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.255 · Cited by 1,020
MacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
Agertoft, L., & Pedersen, S. (1994) · Respiratory Medicine · doi:10.1016/0954-6111(94)90044-2 · Cited by 756
Effects of Reducing or Discontinuing Inhaled Budesonide in Patients with Mild Asthma
Haahtela, T., Jarvinen, M., Kava, T., Kiviranta, K., Koskinen, S., Lehtonen, K., Nikander, K., Persson, T., Selroos, O., Sovijarvi, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409153311103 · Cited by 743
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
Self-citationInhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
Boulet, L. P., Chapman, K. R., Côté, J., Kalra, S., Bhagat, R., Swystun, V. A., Laviolette, M., Cleland, L. D., Deschesnes, F., Su, J. Q., et al. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196083 · Cited by 399
Effect of Early vs Late Intervention With Inhaled Corticosteroids in Asthma
Selroos, O., Pietinalho, A., Löfroos, A. B., & Riska, H. (1995) · CHEST Journal · doi:10.1378/chest.108.5.1228 · Cited by 377
The diverse potential effector and immunoregulatory roles of mast cells in allergic disease
Williams, C. M. M., & Galli, S. J. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.106485 · Cited by 355
Pollart, S. M., Chapman, M. D., Fiocco, G. P., Rose, G., & Platts-Mills, T. A. E. (1989) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(89)90100-0 · Cited by 341
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★
Casale, T. B., Bernstein, I. L., Busse, W. W., LaForce, C. F., Tinkelman, D. G., Stoltz, R. R., Dockhorn, R. J., Reimann, J., Su, J. Q., & Fick Jr., R. B. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70202-1 · Cited by 326
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis
Ädelroth, E., Rak, S., Haahtela, T., Aasand, G., Rosenhall, L., Zetterstrom, O., Byrne, A., Champain, K., Thirlwell, J., Cioppa, G. D., et al. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.108310 · Cited by 317
Prevalence, Impact, and Trends in Childhood Disability Due to Asthma
Newacheck, P. W., & Halfon, N. (2000) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.154.3.287 · Cited by 309
The pharmacological basis of anti-IgE therapy
Chang, T. W. (2000) · Nature Biotechnology · doi:10.1038/72601 · Cited by 288
Mediators of immediate hypersensitivity
Wasserman, S. I. (1983) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(83)90512-2 · Cited by 288
TREATMENT OF ALLERGIC ASTHMA WITH MONOCLONAL ANTI-IgE ANTIBODY
Ilgrom, H. E. M., Ick, R. O. B. F., Ohn, J., Eimann, J. A. D. R., Ush, R. O. K. B., Arc, M., Atrous, L. W., Ames, W. J., & Roup, S. T. G. (1999) · Cited by 281
Gergen, P. J., & Turkeltaub, P. C. (1992) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(92)90130-t · Cited by 257
Hamelmann, E., Tadeda, K., Oshiba, A., & Gelfand, E. (1999) · Allergy · doi:10.1034/j.1398-9995.1999.00085.x · Cited by 206
The binding site on human immunoglobulin E for its high affinity receptor
Presta, L., Shields, R., O'Connell, L., Lahr, S., Porter, J., Gorman, C., & Jardieu, P. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47203-1 · Cited by 198
Inhibition of Allergic Reactions with Antibodies to IgE
Shields, R. L., Whether, W. R., Zioncheck, K., O’Connell, L., Fendly, B., Presta, L. G., Thomas, D., Saban, R., & Jardieu, P. (1995) · International Archives of Allergy and Immunology · doi:10.1159/000237010 · Cited by 183
Nelson, H. S., Szefler, S. J., Jacobs, J., Huss, K., Shapiro, G., & Sternberg, A. L. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70287-3 · Cited by 178
Gern, J. E., Lemanske, R. F., & Busse, W. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8272 · Cited by 175
IgE in asthma and atopy: cellular and molecular connections
Oettgen, H. C., & Geha, R. S. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8205 · Cited by 149
Liu, J., Lester, P. M., Builder, S. E., & Shire, S. J. (1995) · Biochemistry · doi:10.1021/bi00033a020 · Cited by 147
Total serum IgE and its association with asthma symptoms and allergic sensitization among children
Sherrill, D. L., Stein, R. T., Halonen, M. J., Holberg, C. J., Wright, A., & Martínez, F. D. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70110-7 · Cited by 147
Lemanske, R. F., & Kaliner, M. (1983) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1983.tb02158.x · Cited by 147
Fox, J. A., Hotaling, T. E., Struble, C. B., Ruppel, J., Bates, D. J., & Schoenhoff, M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21215-0 · Cited by 123
Standardization and stability of immunoglobulin E (IgE)
Bazaral, M. G., & Hamburger, R. N. (1972) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(72)90113-3 · Cited by 117
Therapeutic potential of anti-IgE antibodies
Heusser, C. H. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80182-3 · Cited by 104
The inflammatory basis of asthma and its implications for drug treatment
Holgate, S. T. (1996) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1996.tb00660.x · Cited by 56
Screening for IgE‐Mediated Allergy
MERRETT, T. G., Pantin, C. F. A., Dimond, A. H., & Merrett, J. (1980) · Allergy · doi:10.1111/j.1398-9995.1980.tb01796.x · Cited by 37
Overbeek, S. E., Rijnbeek, P. R., Vons, C., Mulder, P., Hoogsteden, H., & Bogaard, J. M. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09112256 · Cited by 28
Turkeltaub, P. C., & Gergen, P. J. (1992) · PubMed · Cited by 12
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
“We reviewed all original publications from those reviews and additional RCTs we identified [268-283].”
MethodProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256
The Journal of Allergy and Clinical Immunology
(1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70212-5 · Cited by 1,093
Omalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Metadata
- Authors
- Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2001-08-01
- Volume
- 108
- Issue
- 2
- Pages
- e36-e36
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2160953471
- Cited by
- 525
- References
- 40
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.